Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial
| Autor: | Ammar Alqaid, Bosko Margeta, Rizcallah Dick, Maria Octavia Rangel, Rami Doukky, Marwan Wassouf |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Diarrhea Male Adenosine A2 Receptor Agonists Placebo-controlled study Myocardial Ischemia Placebo Severity of Illness Index law.invention Randomized controlled trial Double-Blind Method law Predictive Value of Tests Risk Factors Severity of illness medicine Clinical endpoint Odds Ratio Humans Radiology Nuclear Medicine and imaging Renal Insufficiency Chronic Infusions Intravenous Aged Chicago Tomography Emission-Computed Single-Photon Chi-Square Distribution business.industry Myocardial Perfusion Imaging Middle Aged medicine.disease Aminophylline Regadenoson Treatment Outcome Purinergic P1 Receptor Antagonists Purines Anesthesia Pyrazoles Female Cardiology and Cardiovascular Medicine business medicine.drug Kidney disease |
| Zdroj: | The international journal of cardiovascular imaging. 29(5) |
| ISSN: | 1875-8312 |
| Popis: | A subgroup analysis of the ASSUAGE trial suggested that the standardized intravenous aminophylline administration following regadenoson-stress leads to substantial attenuation of regadenoson adverse-effects in patients with severe chronic kidney disease (CKD). In a randomized, double-blinded, placebo-controlled clinical trial of patients with stage 4 and 5 CKD, we compared the frequency and severity of regadenoson adverse-effects in those who received 75 mg of intravenous aminophylline versus a matching placebo administered 90 s post-radioisotope injection. Consecutive 300 patients with severe CKD (36 % women; 86 % end-stage renal disease; age 55 (±13) years) were randomized to receive aminophylline (n = 150) or placebo (n = 150). In the aminophylline arm, there was 65 % reduction in the incidence of the primary endpoint of diarrhea (9 (6.0 %) vs. 26 (17.3 %), P = 0.002), 51 % reduction in the secondary endpoint of any regadenoson adverse-effect (47 (31.3 %) vs. 96 (64 %), P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink